BioCryst Pharmaceuticals, Inc.  

(Public, NASDAQ:BCRX)   Watch this stock  
Find more results for BCRX
10.35
-0.18 (-1.71%)
Apr 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 10.33 - 10.70
52 week 7.29 - 14.62
Open 10.53
Vol / Avg. 431,193.00/1.05M
Mkt cap 749.94M
P/E     -
Div/yield     -
EPS -0.68
Shares 72.46M
Beta 2.48
Inst. own 85%
May 20, 2015
BioCryst Pharmaceuticals Inc Annual Shareholders Meeting - 10:00AM EDT - Add to calendar
May 8, 2015
Q1 2015 BioCryst Pharmaceuticals Inc Earnings Call - 11:00AM EDT - Add to calendar
May 8, 2015
Q1 2015 BioCryst Pharmaceuticals Inc Earnings Release - 9:30AM EDT - Add to calendar
Apr 14, 2015
BioCryst Pharmaceuticals Inc at Needham Healthcare Conference
Mar 12, 2015
BioCryst Pharmaceuticals Inc at Barclays Healthcare Conference
Mar 9, 2015
BioCryst Pharmaceuticals Inc at ROTH Conference
Feb 18, 2015
Q4 2014 BioCryst Pharmaceuticals Inc Earnings Call - Webcast
Feb 18, 2015
Q4 2014 BioCryst Pharmaceuticals Inc Earnings Release
Feb 12, 2015
BioCryst Pharmaceuticals Inc at Leerink Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -214.32% -332.08%
Operating margin -278.30% -336.35%
EBITD margin - -335.05%
Return on average assets -34.17% -48.66%
Return on average equity -58.86% -121.30%
Employees 50 -
CDP Score - -

Address

4505 Emperor Blvd Ste 200
DURHAM, NC 27703-8457
United States - Map
+1-919-8591302 (Phone)
+1-919-8591314 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

BioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company. The Company designs, optimizes and develops drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on rare and infectious diseases in which unmet medical needs exist. The Company�s drugs include Peramivir, BCX4161, 2nd generation HAE compounds and BCX4430. Peramivir is a neuraminidase inhibitor for the treatment of patients with influenza. BCX4161 is an inhibitor of plasma kallikrein in development as an orally administered treatment for the prevention of attacks with Hereditary Angioedema (HAE). 2nd generation HAE compounds are once-daily, oral treatments for the prevention of HAE attacks. BCX4430 is a viral RNA-dependent RNA polymerase (RdRp) inhibitor.

Officers and directors

Jon P. Stonehouse President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Thomas R. Staab II Chief Financial Officer, Senior Vice President, Principal Accounting Officer, Treasurer
Age: 50
Bio & Compensation  - Reuters
Yarlagadda S. Babu Ph.D. Senior Vice President - Drug Discovery
Age: 62
Bio & Compensation  - Reuters
Lynne Powell Senior Vice President, Chief Commercial Officer
Age: 48
Bio & Compensation  - Reuters
William P. Sheridan Senior Vice President, Chief Medical Officer
Age: 60
Bio & Compensation  - Reuters
Alane P. Barnes Vice President, General Counsel, and Corporate Secretary
Age: 49
Bio & Compensation  - Reuters
George B. Abercrombie Non-Executive Independent Chairman of the Board
Age: 60
Bio & Compensation  - Reuters
Fred E. Cohen Ph.D., M.D. Director
Age: 58
Bio & Compensation  - Reuters
Stanley C. Erck Independent Director
Age: 66
Bio & Compensation  - Reuters
Nancy J. Hutson Ph.D. Independent Director
Age: 65
Bio & Compensation  - Reuters